期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

微小RNA-21与多发性骨髓瘤的相关性 被引量：3

在线阅读 下载PDF
导出
摘要 多发性骨髓瘤是骨髓浆细胞恶性疾病，平均发病年龄为65岁。随着人口老龄化的加剧，多发性骨髓瘤已逐渐成为威胁老年人健康的主要疾病之一。复发耐药性多发性骨髓瘤患者缺乏有效的治疗方案，是目前该病的主要死亡原因。尽管治疗策略已从传统的化疗、自体造血干细胞移植演变为以沙利度胺与硼替佐米为代表的新型靶向药物治疗，
作者 丁江华 袁利亚 陈国安
机构地区 南昌大学第一附属医院血液科 江西省医学科学研究院血液研究所
出处 《重庆医学》 CAS CSCD 北大核心 2013年第1期85-87,共3页 Chongqing medicine
关键词 微RNAS 多发性骨髓瘤 信号转导 耐药
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献22

  • 1Lagos-Quintana M,Rauhut R, Lendeckel W,et al. Identification of novel genes coding for small expressed RNAs [J]. Science,2001,294(5543) :853-858.
  • 2Mourelatos Z, Dostie J, Paushkin S, et al. miRNPs : a novel class of ribonueleoproteins containing numerous microR NAs[J]. Genes Dev,2002,16(6):720-728.
  • 3Brocke-Heidrich K, Kretzschmar AK, Pfeifer G, et al. In- terleukin-6 dependent survival of multiple myeloma ceils involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer[J]. Blood, 2007,110 (4): 1330-1333.
  • 4Kumarswamy R, Volkmann I, Thum T. Regulation and function of miRNA 21 in health and disease[J]. RNA Bi ol,2011,8(5):706-713.
  • 5Selcuklu SD,Donoghue MT, Spillane C. miR-21 as a key regulator of oncogenic processes[J]. Biochem Soc Trans, 2009,37(Pt 4) :918-925.
  • 6Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogen- esis[J]. Proc Natl Acad Sci U S A,2008,105(35) :12885- 12890.
  • 7Meier C, Hoeller S, Bourgau C, et al. Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas[J]. Mod Pathol,2009,22(3):476- 487.
  • 8Zhong Y,Chen B,Feng J,et al. The associations of Janus kinase 2 (JAK2) A830G polymorphism and the treatment outcomes in patients with acute myeloid leukemia [J]. Leuk Lymphoma,2010,51(6) :1115-1120.
  • 9Munker R, Liu CG, Taccioli C, et al. MicroRNA profiles of drug-resistant myeloma cell lines[J]. Acta Haematol, 2010,123(4) :201-204.
  • 10杨瑞芳,陈丽娟,李建勇,李春溟,许家仁,吴雨洁,陆化.骨髓微环境对多发性骨髓瘤细胞microRNA-21和microRNA-30b表达的影响[J].中华血液学杂志,2010,31(1):38-41. 被引量：3

二级参考文献18

  • 1王学文,杨天楹.难治性和复发性骨髓瘤的治疗进展[J].国外医学（输血及血液学分册）,1993,16(1):35-37. 被引量：11
  • 2Tamm I, Wang Y, Sausville E, et al. IAP-family protein Survivin inhibits caspase activity and apoptosis induced by Fas(CD95), Bax, caspases, and anticancer drugs [J]. Cancer Res, 1998,58(23) :5315-5320.
  • 3Bjorkstrand B, Rasmussen T, Remes K, et al. Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomized phase Ⅱ-study [J]. Eur J Haematol,2003,70(6): 379-383.
  • 4Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, Survivin, expressed in cancer and lymphoma [J]. Nat Med, 1997,3(8) :917-921.
  • 5Adida C, Crotty PL, McGrath J, et al. Developmentally regulated expression of the novel cancer anti-apoptosis gene Survivin in human and mouse differentiation [J]. Am J Pathol,1998,152( 1 ): 43-49.
  • 6Endoh A, Asanuma K, Moriai R, et al. Expression of Survivin mRNA in CD34-positive cells [J]. Clin Chim Acta, 2001,306(1-2): 149-151.
  • 7Konno R, Yamakawa H, Utsunomiya K, et al. Expression of Survivin and Bcl-2 in the normal human endometrium [J]. Mol Hum Reprod, 2000,6(6) :529-534.
  • 8Swana HS, Grossman D, Anthony JN, et al. Tumor content of the antiapoptosis molecule Survivin and recurrence of bladder cancer [ J ]. N Engl J Med, 1999,341 (6): 452-453.
  • 9Carter BZ, Milella M, Alteiri DC, et al. Cytokine-regulated expression of Survivin in myeloid leukemia [J]. Blood, 2001,97 (9): 2784-2790.
  • 10Adida C, Recher C, Raffoux E, et al. Expression and prognostic significance of Survivin in de novo acute myeloid leukaemia [ J ]. Br J Haematol, 2000, 111 ( 1 ): 196-203.

共引文献14

同被引文献43

  • 1杨秀,王庆文,王金泉,陈惠萍,曾彩虹,刘志红,黎磊石,金洁.多发性骨髓瘤肾损害尿蛋白性质的分析及临床意义[J].医学研究生学报,2007,20(3):290-294. 被引量：8
  • 2Rychlik I, Miltenberger - Miltenyi G, Ritz E. The drama of the continuous increase in end - stage renal failure in patients with type II disease mellitus. Nephrol Dial Transplant, 1998,13 ( Suppl 8) :6 - 10.
  • 3Kahn CR, Weir GC, King GL, et al. Joslin s diabetes mellitus. 4th ed. Lippincott :Williams & Wilkins ,2005.
  • 4Gross JL, Deazevedo M J, Silveiro SP, et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care, 2005, 28 (1) :164 -176.
  • 5Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice, nephropathy in patients with type 2 diabetes. N Engl J Med,2002, 346(15) :1145 - 1151.
  • 6Chen Y, Liu W, Chao T,et al. MicroRNA -21 downregulates the expr - ession of tumor suppressor PDCIM in human glioblastoma cell T98G. Cancer Lett,2008,272 (2) : 197 - 205.
  • 7Wang Q, Wang Y, Minto AW, et al. MieroRNA -377 is upregu- lated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J ,2008,22 ( 12 ) :4126 - 4135.
  • 8Korpl M, Lee ES, Hu G, et al. The miR - 200 family inhibits epi- thelial - mesenehymal transition and cancer cell migration by di- rect targeting of E - eadherin transcript ional repressors ZEB1 and ZEB2. J Biol Chem,2008,283 (22) : 14910 - 14914.
  • 9Thum T, Gross C, Fiedler J, et al. MicroRNA -21 contributes to myocardial disease by stimulating MAP kinase signalling in fi- broblasts. Nature,2008,456 (7224) : 980 - 984.
  • 10Liu G, Friggeri A, Yang Y, et al. miR- 21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med,2010,207 (8) : 1589 - 1597.

引证文献3

二级引证文献14

重庆医学
2013年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部